A healthy recovery: The issue facing the pharma industry

Getting the sector back in shape

Matt Crossman of Rathbones

Matt Crossman of Rathbones

Imagine you are a business owner and you are presented with an enormous gap in your market that needs filling and there is a dearth of competition.

But what if the products that would fill that gap are not only unprofitable, but become less valuable the more people use them? What would you do?  This is the issue facing the pharmaceutical industry, which the world depends on to provide the bedrock of modern healthcare - antibiotics. Investment in new antibiotics has slowed to the lowest rate in history, and big pharmaceutical companies have largely abandoned the field.  Modern healthcare systems are built on the ability to control infection, and our tools in that fight - antibiotics - were in crisis even before Covid-19 hit.  C...

To continue reading this article...

Join Investment Week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on ESG

US Supreme Court | Credit: iStock

'Frightening': US Supreme Court deals major blow to federal climate action

Conservative majority on the Court strikes down Environmental Protection Agency’s authority to regulate CO2 from US power plants under Clean Air Act

Michael Holder
clock 30 June 2022 • 4 min read
The listed wind energy sector has undergone a "valuation boom"

European ESG equities Deep Dive: Macro outlook turning favourable

Cautious over 'valuation boom'

Kathleen Gallagher
clock 30 June 2022 • 4 min read
This tool follows the launch of MSCI’s Climate Lab, the Net-Zero Tracker and Implied Temperature Rise.

MSCI launches tool to measure emissions across investment portfolios

Total Portfolio Footprinting

clock 30 June 2022 • 1 min read